Sympazan is an anti-epileptic drug that is produced by Aquestive. It first received permission to be sold on the marketplace on November 01, 2018. clobazam, the active ingredient in Sympazan, is the main reason for its effectiveness in treating epilepsy. The drug currently holds two patents, none of which have expired yet.
The generic version of Sympazan can potentially be available after April 03, 2024. This release date comes from the expiry date of the drug's most relevant patent, US8603514, titled 'Uniform films for rapid dissolve dosage form incorporating taste-masking compositions'.
Sympazan is primarily used for treating epilepsy. Its active ingredient, clobazam, decreases the occurrence of excessive electrical activity in the brain that leads to seizures.
Sympazan has two patents, with the last one expiring on April 03, 2024. This will permit the launch of Sympazan generics. Below are the details of the patent: